Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06412666 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
A Phase 2 study of Pediatric and Symptomatic Obstructive Hypertrophic Cardiomyopathy, sponsored by Cytokinetics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 20
- Study locations
NCT06412666: Recruiting Phase 2 study of Pediatric and Symptomatic Obstructive Hypertrophic Cardiomyopathy, sponsored by Cytokinetics.
NCT06412666 is a Phase 2 study of Pediatric and Symptomatic Obstructive Hypertrophic Cardiomyopathy that is actively recruiting participants, run by Cytokinetics. The registered enrollment target is 55 participants, below the 71-participant average among 8 other Pediatric trials with a reported enrollment target (23% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06412666, a Phase 2 study of Pediatric and Symptomatic Obstructive Hypertrophic Cardiomyopathy, is actively recruiting participants, sponsored by Cytokinetics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aficamten
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- University of California, Los Angeles (UCLA) - Los Angeles
- UCSF Benioff Children's Hospital - San Francisco
Michigan
- University of Michigan - Ann Arbor
- Children's Hospital of Michigan - Detroit
New York
- NYP/Columbia University Medical Center - New York
- Children's Hospital at Montefiore - The Bronx
Arizona
- Phoenix Children's Hospital - Phoenix
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Hospital - Washington D.C.
Florida
- Nicklaus Children's Hospital - Miami
Illinois
- Ann & Robert H. Lurie Children's Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2024-05-29 |
| Est. Completion | 2030-01 |
| Phase | Phase 2 |
What NCT06412666 shows while recruiting
NCT06412666 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 71-participant average among 8 other Pediatric trials with a reported enrollment target (23% lower).
The record links to 2 conditions, with Pediatric appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06412666 names 20 study sites across 16 states, led by California, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT06412666 about?
NCT06412666 is a clinical study titled "A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).". The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
What is the current status of trial NCT06412666?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2024-05-29. Estimated completion is 2030-01.
What conditions does trial NCT06412666 study?
This clinical trial studies the following conditions: Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy.
What interventions are being tested in trial NCT06412666?
The interventions under investigation include: Placebo (DRUG), Aficamten (DRUG).
Who is sponsoring clinical trial NCT06412666?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06412666 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06412666's enrollment target sits among peer trials
55 5th of 8 higher than 4 of 8 other Pediatric trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pediatric trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)
COMPLETED · Phase 2
-
Comparing Two Models of Well-Child Care for Black Families
RECRUITING · NA
-
Quantifying Motor Network Dynamics to Predict and Enhance Outcomes in Pediatric Dystonia
RECRUITING · NA
-
Investigation Of Bioabsorbable Screws In Pediatric Orthopedic Surgery
RECRUITING · NA
-
Pediatric Speech Therapy Session Frequency and Speech Outcomes
ACTIVE NOT RECRUITING · NA
-
Pediatric Adhesion and New Dermal Approach Study
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI